LOGIN  |  REGISTER
Amneal Pharmaceuticals

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 564.71
4.22 0.75
940,302
386.37M
US$ 218.190B
US$ 119.46
0.44 0.37
4.14M
1.74B
US$ 207.860B
US$ 253.84
1.11 0.44
1.31M
739.20M
US$ 187.640B
US$ 389.77
0.69 0.18
986,379
352.33M
US$ 137.330B
US$ 355.03
1.88 0.53
663,349
380.26M
US$ 135.000B
US$ 85.67
0.61 0.72
4.52M
1.33B
US$ 113.940B
US$ 67.00
0.26 0.39
3.66M
1.46B
US$ 97.820B
US$ 246.20
2.58 1.06
973,223
288.90M
US$ 71.130B
US$ 516.24
5.94 1.16
586,094
131.06M
US$ 67.660B
US$ 87.74
0.12 0.14
2.75M
606.50M
US$ 53.210B
US$ 576.29
4.98 0.87
256,194
83.05M
US$ 47.860B
US$ 247.26
-0.07 -0.03
957,373
182.50M
US$ 45.120B
US$ 116.26
-1.24 -1.06
6.21M
385.52M
US$ 44.820B
US$ 80.06
-0.34 -0.42
843,789
491.80M
US$ 39.370B
US$ 132.03
0.01 0.01
1.84M
293.04M
US$ 38.690B
US$ 367.44
7.54 2.10
482,004
73.99M
US$ 27.190B
US$ 184.04
0.94 0.51
663,725
147.09M
US$ 27.070B
US$ 129.18
0.64 0.50
995,644
208.98M
US$ 27.000B
US$ 108.09
0.94 0.88
948,045
243.23M
US$ 26.290B
US$ 1.00
17.01 1.43
66,095
21.48M
US$ 25.990B
US$ 314.19
0.82 0.26
697,650
82.33M
US$ 25.870B
US$ 316.88
0.32 0.10
573,257
76.59M
US$ 24.270B
US$ 235.85
-0.18 -0.08
268,425
98.81M
US$ 23.300B
US$ 42.55
0.54 1.29
3.19M
507.83M
US$ 21.610B
US$ 133.00
-2.55 -1.88
1.27M
158.80M
US$ 21.120B
US$ 331.25
0.70 0.21
233,631
59.13M
US$ 19.590B
US$ 219.16
1.39 0.64
926,605
84.90M
US$ 18.610B
US$ 76.15
0.27 0.36
871,665
234.73M
US$ 17.870B
US$ 127.08
1.74 1.39
765,916
111.44M
US$ 14.160B
US$ 104.44
0.07 0.07
389,707
123.41M
US$ 12.890B
US$ 184.21
-12.93 -6.56
1.92M
69.83M
US$ 12.860B
US$ 247.71
0.81 0.33
356,995
51.30M
US$ 12.710B
US$ 28.88
0.02 0.07
1.12M
437.16M
US$ 12.630B
US$ 401.67
7.98 2.03
311,793
30.76M
US$ 12.360B
US$ 84.67
0.93 1.11
789,147
138.41M
US$ 11.720B
US$ 237.75
0.05 0.02
499,253
46.99M
US$ 11.170B
US$ 196.52
3.12 1.61
430,988
55.83M
US$ 10.970B
US$ 57.53
-1.96 -3.29
2.93M
180.85M
US$ 10.400B
US$ 79.86
2.78 3.61
3.24M
129.94M
US$ 10.380B
US$ 43.82
0.28 0.64
1.30M
221.34M
US$ 9.700B
US$ 260.83
-9.70 -3.59
698,337
36.90M
US$ 9.620B
US$ 238.37
-24.31 -9.25
1.32M
38.60M
US$ 9.200B
US$ 70.46
-0.69 -0.97
562,353
120.15M
US$ 8.470B
US$ 337.99
-0.48 -0.14
253,932
24.06M
US$ 8.130B
US$ 33.91
0.34 1.01
1.95M
211.86M
US$ 7.180B
US$ 132.21
1.20 0.92
336,847
52.84M
US$ 6.990B
US$ 56.29
1.03 1.86
1.17M
115.36M
US$ 6.490B
US$ 17.60
0.28 1.62
679,735
350.86M
US$ 6.180B
US$ 184.94
-0.81 -0.44
321,093
29.59M
US$ 5.470B
US$ 96.75
-1.03 -1.05
1.18M
49.69M
US$ 4.810B
US$ 16.81
0.21 1.27
1.59M
282.62M
US$ 4.750B
US$ 79.81
0.01 0.01
208,503
57.75M
US$ 4.610B
US$ 66.27
1.22 1.88
1.22M
68.49M
US$ 4.540B
US$ 89.57
-1.89 -2.07
912,727
48.80M
US$ 4.370B
US$ 22.65
-0.22 -0.96
1.50M
171.50M
US$ 3.880B
US$ 73.51
-1.39 -1.86
315,677
50.79M
US$ 3.730B
US$ 16.96
-0.25 -1.45
905,026
216.52M
US$ 3.670B
US$ 63.37
-0.01 -0.02
508,380
55.77M
US$ 3.530B
US$ 44.73
-0.12 -0.27
360,138
78.18M
US$ 3.500B
US$ 68.39
0.26 0.38
622,970
50.77M
US$ 3.470B
US$ 69.72
0.32 0.46
156,782
49.65M
US$ 3.460B
US$ 102.00
1.82 1.82
256,394
33.33M
US$ 3.400B
US$ 57.09
-0.01 -0.02
641,199
57.59M
US$ 3.290B
US$ 105.07
-10.00 -8.69
1.15M
30.65M
US$ 3.220B
US$ 46.89
0.34 0.73
1.02M
66.82M
US$ 3.130B
US$ 57.12
0.88 1.56
647,797
53.87M
US$ 3.080B
US$ 83.14
-1.67 -1.97
636,187
32.65M
US$ 2.710B
US$ 21.81
-0.18 -0.82
995,396
124.34M
US$ 2.710B
US$ 28.80
0.48 1.69
919,648
92.66M
US$ 2.670B
US$ 38.65
-0.30 -0.77
218,910
67.89M
US$ 2.620B
US$ 103.59
0.64 0.62
209,551
24.14M
US$ 2.500B
US$ 80.80
-0.56 -0.69
313,038
30.75M
US$ 2.480B
US$ 48.83
-0.33 -0.67
309,803
50.50M
US$ 2.470B
US$ 19.42
-2.85 -12.80
5.34M
121.38M
US$ 2.360B
US$ 38.20
-0.42 -1.09
596,987
57.82M
US$ 2.210B
US$ 16.79
0.34 2.07
1.42M
127.47M
US$ 2.140B
US$ 15.27
-0.12 -0.78
1.16M
136.30M
US$ 2.080B
US$ 22.72
-0.38 -1.65
310,919
89.64M
US$ 2.040B
US$ 54.69
-0.87 -1.57
260,891
35.86M
US$ 1.960B
US$ 29.13
4.13 16.52
4.10M
65.21M
US$ 1.900B
US$ 23.88
0.68 2.93
857,923
76.50M
US$ 1.830B
US$ 21.35
0.66 3.19
1.55M
84.26M
US$ 1.800B
US$ 15.22
-0.02 -0.13
1.44M
106.86M
US$ 1.630B
US$ 33.56
-0.44 -1.29
400,060
47.40M
US$ 1.590B
US$ 30.67
0.17 0.56
426,521
48.82M
US$ 1.500B
US$ 14.24
0.10 0.71
949,457
97.93M
US$ 1.390B
US$ 62.19
1.51 2.49
83,113
22.26M
US$ 1.380B
US$ 5.11
-0.02 -0.39
5.00M
267.44M
US$ 1.370B
US$ 8.20
0.02 0.24
507,654
146.38M
US$ 1.200B
US$ 8.72
0.23 2.71
275,366
135.55M
US$ 1.180B
US$ 7.09
-1.01 -12.47
318,198
156.55M
US$ 1.110B
US$ 13.30
0.01 0.08
218,863
82.70M
US$ 1.100B
US$ 32.17
1.60 5.23
253,684
34.10M
US$ 1.100B
US$ 7.49
-0.03 -0.40
704,443
136.39M
US$ 1.020B
US$ 36.95
0.19 0.52
135,947
27.19M
US$ 1.000B
US$ 40.00
0.33 0.83
40,440
24.22M
US$ 968.800M
US$ 24.87
-0.64 -2.51
255,983
37.83M
US$ 940.830M
US$ 19.69
0.10 0.51
169,755
46.43M
US$ 914.210M
US$ 14.25
-0.14 -0.97
468,554
61.68M
US$ 878.940M
US$ 20.27
0.56 2.84
252,086
41.05M
US$ 832.080M
US$ 20.27
0.07 0.35
464,141
40.50M
US$ 820.940M
US$ 17.50
-0.29 -1.63
302,547
45.05M
US$ 788.380M
US$ 24.06
-0.22 -0.91
201,175
29.63M
US$ 712.900M
US$ 2.45
0.10 4.26
1.18M
289.81M
US$ 710.030M
US$ 17.21
0.14 0.82
204,885
40.62M
US$ 699.070M
US$ 17.00
-0.29 -1.68
510,716
38.95M
US$ 662.150M
US$ 28.30
-0.04 -0.14
118,560
23.36M
US$ 661.090M
US$ 0.95
-0.02 -2.48
6.36M
696.99M
US$ 659.350M
US$ 23.87
-0.50 -2.05
167,916
26.91M
US$ 642.210M
US$ 10.19
0.18 1.80
264,932
61.90M
US$ 630.760M
US$ 350.32
10.15 2.98
4,549
1.76M
US$ 616.560M
US$ 15.30
-1.21 -7.33
591,250
36.27M
US$ 554.930M
US$ 42.39
0.56 1.34
72,227
12.61M
US$ 534.540M
US$ 19.56
0.26 1.35
156,919
26.54M
US$ 519.120M
US$ 6.96
0.25 3.73
593,077
73.48M
US$ 511.420M
US$ 9.12
-0.33 -3.49
134,455
55.08M
US$ 502.330M
US$ 13.65
0.22 1.64
248,316
36.76M
US$ 501.770M
US$ 8.62
-0.27 -3.04
4.85M
57.73M
US$ 497.630M
US$ 17.02
0.48 2.90
55,814
28.67M
US$ 487.950M
US$ 4.59
0.08 1.77
265,598
103.58M
US$ 475.430M
US$ 0.96
0.01 1.05
1.13M
494.60M
US$ 474.820M
US$ 22.21
-0.12 -0.54
79,080
20.88M
US$ 463.740M
US$ 8.27
0.00 0.00
356,237
54.10M
US$ 447.410M
US$ 17.02
1.71 11.17
105,944
26.28M
US$ 447.290M
US$ 10.37
0.14 1.37
158,751
43.04M
US$ 446.320M
US$ 12.91
0.32 2.54
152,844
33.90M
US$ 437.650M
US$ 17.10
0.09 0.53
431,563
25.55M
US$ 436.910M
US$ 10.81
-1.05 -8.85
1.14M
38.31M
US$ 414.130M
US$ 0.73
0.04 5.04
3.54M
528.28M
US$ 385.640M
US$ 15.84
1.71 12.10
533,184
23.50M
US$ 372.240M
US$ 8.59
0.39 4.76
98,223
38.76M
US$ 332.950M
US$ 47.34
-0.38 -0.80
32,226
6.87M
US$ 325.230M
US$ 37.97
0.00 0.00
7,704
8.54M
US$ 324.260M
US$ 4.78
0.41 9.38
191,588
62.97M
US$ 301.000M
US$ 5.49
0.14 2.62
147,253
49.08M
US$ 269.450M
US$ 2.64
0.03 1.15
301,776
99.17M
US$ 261.810M
US$ 8.47
-0.13 -1.51
336,818
30.37M
US$ 257.230M
US$ 70.55
-1.12 -1.56
104,594
3.63M
US$ 256.100M
US$ 3.05
0.24 8.54
291,231
80.88M
US$ 246.680M
US$ 9.20
-0.15 -1.60
6,356
26.41M
US$ 242.970M
US$ 5.79
-0.20 -3.34
326,489
39.86M
US$ 230.790M
US$ 7.03
-0.08 -1.13
184,438
32.38M
US$ 227.630M
US$ 6.01
-0.03 -0.50
15,831
36.93M
US$ 221.950M
US$ 4.43
0.13 3.02
154,002
48.75M
US$ 215.960M
US$ 9.19
-0.18 -1.92
269,296
23.31M
US$ 214.220M
US$ 8.20
-0.44 -5.09
52,528
24.42M
US$ 200.240M
US$ 9.21
-0.09 -0.97
22,207
21.18M
US$ 195.070M
US$ 1.56
0.00 0.00
234,705
121.79M
US$ 189.990M
US$ 4.41
0.01 0.23
23,431
42.69M
US$ 188.260M
US$ 4.44
-0.06 -1.33
84,559
42.10M
US$ 186.920M
US$ 3.72
0.31 9.09
1.21M
50.20M
US$ 186.740M
US$ 1.02
0.03 3.52
1.10M
180.70M
US$ 184.310M
US$ 0.57
-0.04 -5.83
5.66M
315.44M
US$ 178.260M
US$ 7.07
0.01 0.14
40,544
24.49M
US$ 173.140M
US$ 22.82
0.43 1.92
14,725
6.33M
US$ 144.450M
US$ 5.58
-0.37 -6.22
678,215
25.79M
US$ 143.910M
US$ 1.58
0.11 7.48
51,274
90.48M
US$ 142.960M
C$ 0.51
-0.03 -5.56
324,659
278.58M
C$ 142.080M
US$ 1.04
0.12 13.04
159,574
130.11M
US$ 135.310M
US$ 2.85
0.10 3.64
35,226
47.47M
US$ 135.290M
US$ 14.98
0.48 3.31
23,013
8.61M
US$ 128.980M
US$ 3.93
0.00 0.00
6,050
31.62M
US$ 124.270M
US$ 6.03
-0.31 -4.89
156,954
16.62M
US$ 100.220M
US$ 3.57
-0.03 -0.83
22,156
27.29M
US$ 97.430M
US$ 2.10
0.02 0.96
113,730
45.67M
US$ 95.910M
US$ 4.32
0.04 0.93
141,216
22.05M
US$ 95.260M
US$ 3.29
0.01 0.30
96,774
28.93M
US$ 95.180M
US$ 2.40
1.95 435.95
63,090
38.21M
US$ 91.700M
US$ 2.94
-0.12 -3.92
48,958
31.13M
US$ 91.520M
US$ 0.81
0.01 1.36
18,219
102.68M
US$ 83.170M
US$ 1.04
0.07 7.14
71,867
78.69M
US$ 81.840M
US$ 0.31
0.02 7.09
583,440
264.90M
US$ 80.850M
US$ 2.86
-0.09 -3.05
111,877
27.87M
US$ 79.710M
US$ 4.86
0.13 2.75
89,464
16.37M
US$ 79.560M
US$ 5.85
0.31 5.60
150,133
13.32M
US$ 77.920M
US$ 1.38
0.03 2.22
100,821
50.49M
US$ 69.680M
US$ 2.01
-0.13 -6.07
133,447
34.64M
US$ 69.630M
C$ 0.63
0.03 5.00
49,550
108.55M
C$ 68.390M
C$ 0.99
-0.01 -1.00
8,700
65.03M
C$ 64.380M
US$ 1.75
-0.11 -5.91
302,396
36.04M
US$ 63.070M
US$ 3.50
0.00 0.00
0
17.64M
US$ 61.740M
US$ 1.32
0.02 1.54
42,512
45.73M
US$ 60.360M
US$ 3.15
-0.21 -6.25
15,052
18.88M
US$ 59.470M
US$ 1.03
0.00 0.00
44,760
56.54M
US$ 58.240M
US$ 16.55
-0.56 -3.27
6,913
3.51M
US$ 58.090M
US$ 1.92
-0.04 -2.04
4,870
29.87M
US$ 57.350M
US$ 2.63
-0.06 -2.25
8,330
21.55M
US$ 56.670M
US$ 2.03
0.005 0.25
91,445
27.21M
US$ 55.240M
US$ 1.07
-0.02 -1.83
31,818
51.03M
US$ 54.600M
US$ 0.35
-0.0023 -0.65
177,466
155.27M
US$ 54.340M
C$ 1.03
0.05 5.10
174,626
52.65M
C$ 54.230M
C$ 0.53
0.01 1.92
500
101.40M
C$ 53.740M
US$ 2.57
0.00 0.00
0
20.76M
US$ 53.350M
US$ 1.24
-0.01 -0.80
59,832
42.88M
US$ 53.170M
US$ 6.17
1.15 22.91
155,808
8.57M
US$ 52.880M
US$ 4.69
0.32 7.32
10,718
11.25M
US$ 52.760M
US$ 0.69
0.01 1.94
31,974
76.19M
US$ 52.570M
US$ 0.98
-0.01 -1.01
73,061
52.17M
US$ 51.130M
US$ 2.40
-0.25 -9.28
1.68M
20.02M
US$ 47.950M
US$ 4.46
0.05 1.13
14,054
10.34M
US$ 46.120M
C$ 0.20
-0.005 -2.44
6,000
228.46M
C$ 45.690M
C$ 0.29
0.005 1.79
107,845
156.82M
C$ 44.690M
US$ 1.14
-0.02 -1.72
885,910
38.84M
US$ 44.280M
US$ 1.27
-0.03 -2.31
167,363
34.24M
US$ 43.480M
US$ 1.59
0.04 2.58
56,393
26.33M
US$ 41.860M
US$ 2.55
0.07 2.82
18,972
16.25M
US$ 41.440M
US$ 6.88
-0.05 -0.72
7,368
6.00M
US$ 41.280M
US$ 0.55
0.03 6.03
164,887
73.38M
US$ 40.360M
US$ 3.72
0.18 5.08
10,525
10.48M
US$ 38.990M
US$ 1.78
0.03 1.71
329,074
21.90M
US$ 38.980M
US$ 1.30
-0.04 -2.99
42,541
29.94M
US$ 38.920M
US$ 1.00
0.05 5.26
33,501
37.10M
US$ 37.100M
C$ 0.30
-0.02 -6.25
22,645
118.47M
C$ 35.540M
US$ 2.05
0.07 3.53
5,049
17.05M
US$ 34.950M
US$ 1.13
0.01 0.89
99,604
30.58M
US$ 34.560M
US$ 1.92
0.00 0.00
39,159
17.82M
US$ 34.210M
US$ 0.59
-0.52 -46.76
729,990
55.68M
US$ 33.020M
US$ 1.42
-0.04 -2.74
831,799
21.65M
US$ 30.740M
US$ 1.87
0.00 0.00
185,801
16.29M
US$ 30.460M
US$ 0.02
-0.0015 -5.75
30,750
1.14B
US$ 28.040M
US$ 1.07
-0.03 -2.73
23,581
25.93M
US$ 27.750M
C$ 0.30
0.01 3.45
20,000
90.89M
C$ 27.270M
US$ 0.92
0.07 8.33
9,730
27.87M
US$ 25.660M
US$ 1.26
0.05 4.13
30,168
19.55M
US$ 24.630M
US$ 0.78
0.32 70.27
21.13M
29.95M
US$ 23.360M
C$ 0.12
0.00 0.00
672,186
194.28M
C$ 23.310M
C$ 0.32
0.00 0.00
0
69.23M
C$ 22.150M
US$ 5.42
-0.06 -1.09
89,939
4.05M
US$ 21.950M
US$ 1.29
0.14 12.50
200,501
16.82M
US$ 21.700M
US$ 0.06
0.0049 9.61
1.04M
371.00M
US$ 20.740M
US$ 1.20
0.00 0.00
5,191
16.77M
US$ 20.120M
US$ 0.97
0.02 2.11
66,632
20.27M
US$ 19.660M
US$ 0.94
-0.02 -1.71
172,553
20.36M
US$ 19.040M
US$ 0.52
0.01 2.37
24,075
35.05M
US$ 18.300M
US$ 3.10
0.04 1.31
7,490
5.80M
US$ 17.980M
US$ 1.80
0.38 26.75
315,111
9.50M
US$ 17.100M
US$ 1.26
-0.0088 -0.69
25,945
13.39M
US$ 16.870M
US$ 1.20
-0.07 -5.51
393,432
14.00M
US$ 16.800M
US$ 0.69
-0.03 -3.76
238,103
24.23M
US$ 16.760M
US$ 8.52
-0.29 -3.29
1,196
1.82M
US$ 15.510M
US$ 1.89
0.04 2.16
19,149
8.05M
US$ 15.210M
C$ 0.14
0.00 0.00
12,500
99.64M
C$ 13.950M
US$ 3.42
-0.09 -2.56
16,261
4.06M
US$ 13.890M
US$ 2.35
0.03 1.08
17,129
5.72M
US$ 13.440M
US$ 2.26
0.03 1.35
4,951
5.85M
US$ 13.220M
US$ 1.15
0.00 0.00
151,715
11.04M
US$ 12.700M
US$ 0.65
-0.0075 -1.14
139,934
16.98M
US$ 11.040M
C$ 0.15
0.00 0.00
0
71.31M
C$ 10.700M
US$ 1.00
-0.0099 -0.98
45,317
10.04M
US$ 10.040M
US$ 0.18
-0.05 -21.74
119,826
54.28M
US$ 9.770M
US$ 0.53
0.01 2.78
171,278
17.39M
US$ 9.250M
US$ 1.05
-0.05 -4.55
19,024
8.77M
US$ 9.210M
US$ 4.26
-0.05 -1.16
94,100
2.15M
US$ 9.160M
US$ 6.21
-0.13 -2.05
288
1.42M
US$ 8.820M
C$ 0.15
-0.03 -14.29
500
54.90M
C$ 8.240M
US$ 0.12
0.0022 1.89
1.18M
63.61M
US$ 7.560M
US$ 1.95
0.0034 0.17
2,024
3.85M
US$ 7.520M
US$ 1.30
-0.56 -30.11
934,151
5.53M
US$ 7.190M
C$ 0.08
-0.005 -6.25
2,000
94.47M
C$ 7.090M
US$ 0.09
0.00 0.00
0
73.90M
US$ 6.670M
US$ 4.90
-0.05 -1.01
60,940
1.33M
US$ 6.520M
US$ 0.22
-0.0039 -1.75
620,717
29.30M
US$ 6.410M
US$ 0.99
-0.28 -22.05
4,507
6.14M
US$ 6.080M
C$ 0.03
-0.005 -14.29
538,571
188.08M
C$ 5.640M
US$ 0.02
0.00 0.00
0
286.49M
US$ 5.440M
US$ 0.35
-0.01 -3.05
116,954
15.27M
US$ 5.340M
US$ 0.44
0.02 4.82
11,600
11.77M
US$ 5.120M
US$ 5.74
-0.06 -1.03
10,185
886,743
US$ 5.090M
US$ 0.06
0.0008 1.32
14,615
83.12M
US$ 5.090M
C$ 0.02
0.00 0.00
21,000
246.29M
C$ 4.930M
C$ 0.04
0.00 0.00
3,000
122.72M
C$ 4.910M
US$ 1.70
-0.0066 -0.39
3,287
2.62M
US$ 4.450M
US$ 3.42
-0.14 -3.93
25,869
1.28M
US$ 4.380M
US$ 0.42
0.004 0.95
76,683
10.01M
US$ 4.240M
US$ 0.47
0.03 7.89
108,368
9.08M
US$ 4.220M
US$ 0.15
-0.0054 -3.39
445,023
23.46M
US$ 3.610M
US$ 0.61
0.01 1.83
1.12M
5.68M
US$ 3.470M
US$ 3.11
0.17 5.78
90,212
1.09M
US$ 3.390M
US$ 1.05
0.00 0.00
27,008
3.14M
US$ 3.300M
US$ 0.33
-0.0006 -0.18
312,660
9.33M
US$ 3.070M
US$ 0.10
-0.0033 -3.13
39,873
28.90M
US$ 2.950M
US$ 0.41
-0.006 -1.44
14,377
7.03M
US$ 2.880M
US$ 0.15
-0.0026 -1.71
3.14M
19.20M
US$ 2.870M
US$ 0.02
0.00 0.00
0
161.02M
US$ 2.580M
US$ 1.03
-0.05 -4.63
18,845
2.47M
US$ 2.540M
US$ 1.01
0.09 9.78
20,566
2.49M
US$ 2.510M
US$ 0.50
0.0021 0.42
515
4.88M
US$ 2.440M
US$ 0.31
0.002 0.65
21,159
7.29M
US$ 2.270M
US$ 0.17
0.00 0.00
0
11.96M
US$ 2.080M
US$ 1.00
0.00 0.00
41,883
2.05M
US$ 2.050M
US$ 3.60
0.00 0.00
22,302
534,238
US$ 1.920M
US$ 1.24
-0.03 -2.36
19,960
1.47M
US$ 1.820M
C$ 0.04
0.00 0.00
0
48.23M
C$ 1.690M
C$ 0.01
-0.005 -33.33
9,500
160.81M
C$ 1.610M
US$ 0.75
-0.02 -2.72
59,561
1.78M
US$ 1.340M
US$ 0.82
0.03 3.86
997,524
1.55M
US$ 1.270M
US$ 0.05
0.00 0.00
0
9.74M
US$ 487K
US$ 0.0007
0.00 0.00
927,787
463.12M
US$ 324K
US$ 0.88
0.00 0.00
142,642
-
US$ -
US$ 4.95
0.00 0.00
55,379
-
US$ -
US$ 0.41
0.00 0.00
0
-
US$ -
C$ 1.32
0.00 0.00
187,973
-
C$ -
C$ 0.19
0.00 0.00
319,000
-
C$ -

Latest News From Medical Stocks


Quanterix to Present at Cowen’s 44th Annual Health Care Conference

BILLERICA, Mass. / Feb 23, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will present at Cowen’s 44th Annual Health Care Conference. Quanterix’s session will take place on Monday, March 4, 2024, at 12:50 p.m. EST and will be made available to attendees and, via webcast, the general public. In addition to the session,... Read more


Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TORONTO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 817,748 shares of common stock at a purchase price of $1.465 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered... Read more


Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)

Represents 8th Consecutive Year of 20% or More Constant Currency Revenue Growth ACTON, Mass. / Feb 22, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2023. Full Year Financial Highlights: Full year 2023 revenue of $1.7 billion, up 30.0%, or 29.6% in... Read more


Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook

Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 million PALO ALTO, Calif. / Feb 22, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue of $155.1 million for the fourth quarter of 2023, an... Read more


Penumbra Reports Fourth Quarter and Full Year 2023 Financial Results

ALAMEDA, Calif., Feb. 22, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023. Financial Highlights: Revenue of $284.7 million for the fourth quarter of 2023, an increase of 28.7% or 27.9% in constant currency1 compared to the fourth quarter of 2022. Revenue of $1,058.5 million for the full year 2023,... Read more


iRhythm Technologies Announces Fourth Quarter and Full Year 2023 Financial Results

SAN FRANCISCO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Grew fourth quarter 2023 patient registrations in excess of 22% compared to the fourth quarter 2022 Revenue of $132.5 million,... Read more


AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

VALENCIA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Commercial revenue increased approximately 50% to $14.1 million compared to the same period in 2022 Gross... Read more


Waters to Present at the TD Cowen 44th Annual Health Care Conference

MILFORD, Mass., Feb. 22, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Monday, March 4th, 2024 at 11:10AM Eastern Time A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will... Read more


Sanara MedTech Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023

FORT WORTH, TX, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today certain unaudited preliminary results for... Read more


ReShape Lifesciences Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

FLEX Technology Designed to Enhance the Patient Experience Surgeon Training Underway for the Initial Launch of the Lap-Band® 2.0 FLEX IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Adam Smith, D.O., Bariatric Surgery Specialist and Chief Executive Officer of Ultimate Bariatrics in Dallas, Fort Worth, TX, and Christine Ren-Fielding,... Read more


ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company’s Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2. “This... Read more


Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference

AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2, 2024. Management... Read more


Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. / Feb 22, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a fireside chat at the TD Cowen 44th Annual Health... Read more


Tenon Medical Announces Issuance of Notice of Allowance of Patent Application Which Further Enhances Important Claims for its Sacroiliac Joint Implant

Received Notice of Allowance from the USPTO on February 15, 2024 LOS GATOS, CA / ACCESSWIRE / February 22, 2024 / Tenon Medical, Inc. ("Tenon" or the "Company") (NASDAQ:TNON), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced that on February 15, 2024, the United States Patent and Trademark Office ("USPTO") issued a Notice of Allowance for U.S. Patent Application Serial Number 18/107,536 for Tenon's Catamaran®... Read more


Spectral AI Receives UKCA Authorization for Burn Indication Expected Commercialization 2nd Half 2024

DALLAS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that its predictive software DeepView AI®-Burn has obtained the final stage of UK Conformity Assessed (UKCA) authorization, for aiding in burn wound diagnosis in the United Kingdom. "I am delighted to announce... Read more


Venus Concept Announces CE Mark for Venus Versa Pro in Europe

TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received the CE Mark from DEKRA Certification B.V. to market the Venus Versa Pro system in the European Union. This follows the Company’s announcement on November 1, 2023 regarding the commercial launch of the device in the United States. The Venus Versa Pro i... Read more


Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC accepted for review by U.S. Food and Drug Administration Enrollment completed in phase 3 TRIDENT trial studying the use of TTFields therapy and concomitant radiation for the treatment of newly diagnosed GBM ROOT, Switzerland / Feb 22, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full... Read more


Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies

RA'ANANA, Israel, Feb. 22, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company targeting to supersede mechanical ventilators, has unveiled an exclusive in-house capability designed to simulate both the arterial and venous blood parameters of patients with specific medical conditions without the need of in vivo animal testing. This platform has... Read more


Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results

Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023 GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023 GAAP fully diluted net income per share of $1.47 and $4.65 for the fourth quarter and full year 2023 Adjusted fully diluted net income per share of $1.75 and $6.23 for the fourth quarter and full year 2023 Net cash provided by operating activities was $112.3 million and $305.3... Read more


Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry

Waterlase iPlus Premier Edition™ is being unveiled at the Chicago Midwinter Meeting 2024 LAKE FOREST, CA / ACCESSWIRE / February 22, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, and will be debuting it at the Chicago Midwinter Meeting 2024 from February 22nd to 24th at booth 4608. The Waterlase iPlus Premier Edition™ is... Read more


Teleflex Reports Fourth Quarter and Full Year 2023 Financial Results

WAYNE, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2023. Fourth quarter financial summary Revenues of $773.9 million, reflective of five fewer shipping days year-over-year, up 2.1% compared to the prior year period; up 0.7% on a constant currency basis GAAP diluted EPS from continuing operations of $0.66, compared to $1.65 in the... Read more


RetinalGeniX Technologies Granted a Patent for System And Method For Visualization Of Ocular Anatomy

PETALUMA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”) today announced that it has been granted a patent by the United States Patent and Trademark Office for the Company's System And Method For Visualization Of Ocular Anatomy. The present invention relates to systems and methods for visualizing eye anatomy for diagnostic and therapeutic purposes. It is an objective of this invention to... Read more


Motus GI Announces Exercise of Warrants for $2.7 Million Gross Proceeds

FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company’s common... Read more


Owlet Announces Strong Preliminary Fourth Quarter 2023 Results and to Report Fourth Quarter 2023 Financial Results on March 7, 2024

LEHI, Utah / Feb 22, 2024 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the following preliminary unaudited results for the fourth quarter 2023. Preliminary Unaudited Q4 2023 Financial Highlights Q4 Gross Sales is expected to be approximately $32.9 million, up 114% year over year. Q4 Net Revenue is expected to be approximately $21.0 million, up 75% year over year. Q4 Gross Margin... Read more


NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "Quell® Fibromyalgia growth accelerated in Q4 2023 reflecting the addition in Q3 2023 of two field business development managers and optimized clinical... Read more


Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference

BOSTON, Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5, 2024 at 7:30 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://wsw.com/webcast/rj129/hae/1445840. A replay of the... Read more


Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day

BOSTON, Feb. 21, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at 8:45 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://kvgo.com/unplugged-medtech-life-sciences-access-da... Read more


MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6

MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 Company to Host Conference Call with Live Q&A, March 6, 2024 at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 21, 2024 – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2023, after market close... Read more


IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024

RESEARCH TRIANGLE PARK, N.C. / Feb 21, 2024 / Business Wire / IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 29, 2024 at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast... Read more


ICON Reports Fourth Quarter and Full Year 2023 Results

Highlights Net business wins in the quarter of $2,531 million; a net book to bill of 1.22. Full year net business wins of $9,946 million; a net book to bill of 1.22. Closing backlog of $22.8 billion, an increase of 2.4% on quarter three 2023 and an increase of 10.0% on quarter four 2022. Quarter four revenue of $2,066.2 million representing an increase of 5.3% on prior year revenue. Full year revenue of $8,120.2 million representing a year on year increase of 4.9%. Quarter... Read more


Exact Sciences Announces Fourth Quarter 2023 Results

Reports record revenue, generates positive free cash flow, expects 2024 revenue of $2.810-2.850 billion Fourth quarter and 2023 highlights Total fourth quarter revenue of $647 million, an increase of 17%, or 18% on a core revenue basis, with Screening revenue of $487 million and Precision Oncology revenue of $160 million Total 2023 revenue of $2.50 billion, an increase of 20%, or 24% on a core revenue basis, with Screening revenue of $1.865 billion and Precision Oncology... Read more


Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance

SAN DIEGO / Feb 21, 2024 / Business Wire / Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2023 and provided its financial guidance for the year ending December 31, 2024. Fourth Quarter and Recent Highlights Worldwide installed base increased 7 percent to approximately 452,000 in-warranty customers compared to the fourth quarter 2022.... Read more


Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

ALISO VIEJO, Calif. / Feb 21, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highlights include: Record net sales of $82.4 million in Q4 2023 increased 16% year-over-year on a reported basis and 15% year-over-year... Read more


Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2023 ended December 31, 2023. Recent Highlights Delivered $68.7 million in worldwide revenue for the full year of 2023, a 28% increase over the prior year Achieved record worldwide revenue of $19.3 million... Read more


Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results

Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2023 financial results. The company also provided first-quarter and full-year 2024 financial guidance. "Our fourth quarter performance reflects continued execution of... Read more



Hyperfine Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes

The collaboration kicked off at the 2024 All-Star game in Indianapolis Athletic Heart will use the Swoop® Portable MR Imaging® system to provide brain imaging GUILFORD, Conn. & ORLANDO, Fla. / Feb 21, 2024 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system–the Swoop® system, and Athletic Heart... Read more


Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

SAN FRANCISCO / Feb 21, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that enrollment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed. VNS is a growing market that is part of the $8.3B global neurostimulation market, which has a projected CAGR of 12.2%, according to Global... Read more


Motus GI Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.” “We are pleased to announce further strengthening our IP portfolio... Read more


Charles River Laboratories and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing

WILMINGTON, Mass. & OKLAHOMA CITY / Feb 21, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler’s Portable CMC® (Chemistry, Manufacturing and Controls) platform. This new alliance provides early-stage... Read more


Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices

Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System SAN DIEGO, Feb. 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held... Read more


Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass. / Feb 21, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced it will present at the following investor conferences in February and March 2024: Citi's 2024 Unplugged MedTech and Life Sciences Access Day - New York City, NY Thursday, February 29, 2024 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 44th Annual Health Care Conference – Boston, MA Monday, March 4, 2024 9:10 a.m. ET - Prahlad Singh, president... Read more


Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy. TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan. The partnership signifies a major step forward... Read more


Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia

NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is preparing to make the first shipment of its 1mL and 3mL Securegard smart safety syringe line to the Latin American healthcare market. The initial product orders have been placed through a collaborative effort between Sharps and a Latin American... Read more


Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery

Grocery Delivery Services Now Available via Instacart to Individuals Participating in the Coaching Programs of Pack Health, a Quest Diagnostics Company, to Mitigate Social Determinants of Health Impacting Care BIRMINGHAM, Ala. and SAN FRANCISCO, Feb. 21, 2024 /PRNewswire/ -- Pack Health, a Quest Diagnostics (NYSE: DGX) company specializing in patient engagement, and Instacart (NASDAQ: CART), the leading grocery technology company in North America, today announced... Read more


Apyx Medical Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting

Presentation hosted by Dr. Michael Kluska to feature the results of a retrospective clinical study comparing the use of Renuvion to a competing technology when used in conjunction with liposuction or body contouring, demonstrating significantly fewer adverse events CLEARWATER, Fla. / Feb 21, 2024 / Business Wire / Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology... Read more


Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of 1.03 WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023. The company... Read more


CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

BRISBANE, Calif. / Feb 21, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular therapy and transplant monitoring... Read more


Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Fourth-Quarter 2023 Financial Results Revenue of $1.173 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $54 Million Adjusted EBITDA (non-GAAP)1 of $231 Million Revenue Grew 18% as Reported and 19% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2022, Driven by Growth Across All Segments Full-Year 2023 Financial Results Revenue of $4.146 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $260 Million Adjusted... Read more


Becton Dickinson Partners with Camtech Health to Increase Access to Cervical Cancer Screening in Singapore

First-Ever Program in the Country to Offer At-Home Self-Collection of Samples for HPV Testing SINGAPORE, Feb. 21, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB